Quantum Biopharma Appoints Dr. Salvatore Napoli As Principal Investigator For Phase 2 Clinical Trial Of Lucid-21-302 For Treatment Of Demyelination In Multiple Sclerosis

Benzinga Newsdesk www.benzinga.com Neutral 61.7%

Neg 0% Neu 61.7% Pos 0%

Comments

No comments yet. Be the first!